...
首页> 外文期刊>American Journal of Physiology >A growing chain of evidence linking genetic variation in angiotensinogen with essential hypertension: focus on 'A haplotype of human angiotensinogen gene containing -217A increases blood pressure in t
【24h】

A growing chain of evidence linking genetic variation in angiotensinogen with essential hypertension: focus on 'A haplotype of human angiotensinogen gene containing -217A increases blood pressure in t

机译:越来越多的证据将血管紧张素原的遗传变异与原发性高血压联系起来:着眼于“含有-217A的人类血管紧张素原基因单倍型会增加血压

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

the prevalence of hypertension across the globe continues to rise despite advances in treatment and an ever-growing battery of antihypertensive drugs. Untreated hypertension remains an important risk factor for cardiovascular diseases, including stroke. The renin-angiotensin system (RAS) has long been recognized as a critical mediator of blood pressure regulation, RAS blockers are particularly effective antihypertensive agents. Continued interest in clinically blocking the system is evidenced by the recent FDA approval of the renin inhibitor aliskiren as a first-line antihypertensive (16). Despite the impact of environmental and behavioral factors, it is now widely accepted that there exists a strong genetic component that influences the susceptibility to hypertension
机译:尽管治疗水平不断提高,并且抗高血压药物的数量不断增长,但全球高血压的患病率仍在继续上升。未经治疗的高血压仍然是包括中风在内的心血管疾病的重要危险因素。肾素-血管紧张素系统(RAS)一直被认为是血压调节的关键介质,RAS阻滞剂是特别有效的降压药。 FDA最近批准了肾素抑制剂阿利吉仑作为一线抗高血压药,证明了对临床阻断该系统的持续兴趣(16)。尽管受到环境和行为因素的影响,但现在已经广泛接受存在影响高血压易感性的强大遗传成分

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号